1. 首页
  2. ›JD.com Q3 Net Profit Reaches RMB 6.5 Billion, Up 23% YoY, 44% Growth on Non-GAAP Basis

JD.com Q3 Net Profit Reaches RMB 6.5 Billion, Up 23% YoY, 44% Growth on Non-GAAP Basis

N
nashnova research
·今天发布·阅读约 13 分钟

JD.com posted Q3 net profit of RMB 6.5 billion, up 23% year-on-year, while non-GAAP profit surged 44%; revenue returned to growth, but the real test is whether new-business loss narrowing and overseas synergies can hold.

01

What do the headline numbers actually say?

•
Q3 net revenue hit RMB 309.6 billion, slightly above the consensus estimate of RMB 309.1 billion. Net profit attributable to shareholders reached RMB 6.5 billion, up 23% year-on-year.
•
On a non-GAAP basis, net profit rose 44% to RMB 8.3 billion, accelerating from the prior quarter. This means → strip out one-off and non-cash items, and JD's actual earnings power improved nearly twice as fast as the headline figure suggests.
•
Year-to-date revenue totalled RMB 971.7 billion, up just 1.56%. In plain terms = profit is running far ahead of revenue — JD is earning more by spending less, not by selling more.
02

What is driving the profit acceleration?

•
CEO Xu Ran flagged two lines: retail resilience + new-business loss narrowing. User base expanded while marketing expenses fell meaningfully year-on-year — more users acquired for less money.
•
The retail segment acted as an "anchor" — operating margin held roughly stable against a high base. This means → retail delivered no upside surprise but no drag either; the profit acceleration came mainly from new businesses bleeding less.
•
New businesses narrowed losses both year-on-year and quarter-on-quarter, led by JD Takeaway and Jingxi. CFO Shan Su pledged to "keep improving efficiency and maintain financial discipline."
03

Where does the overseas push stand?

•
The acquisition of European consumer-electronics retailer CECONOMY is complete. Xu Ran called it "an important step" in JD's global retail and logistics footprint.
•
Cross-border platform Joybuy is showing good momentum; the CFO expects further acceleration as CECONOMY synergies materialise.
•
This reflects a shift from "Chinese e-commerce company" to "global retail-plus-logistics company" — but the market is still waiting to see synergies show up in actual financial results.
04

How is subsidiary JD Health performing?

•
JD Health (06618) posted Q3 revenue of RMB 20 billion, maintaining double-digit growth; non-IFRS operating profit came in at RMB 1.57 billion.
•
AI doctor "Dawei" saw daily health-service interactions jump more than 5× year-on-year; the AI clinical workstation "Medwork" has launched specialist pilots with Peking University Cancer Hospital and other institutions. In plain terms = AI in JD's health arm has moved beyond concept stage into real hospital workflows.
•
Yet profitability is under pressure as AI healthcare and supply-chain expansion costs are still ramping. This means → when AI spending converts into profit is the single most important number to watch for JD Health going forward.
05

What is new on the supply-chain and fulfilment side?

•
Over 110 pharmaceutical companies have chosen JD Health for new-drug launches; Q3 alone saw more than 50 launches, with cumulative online launches exceeding 100 — surpassing the full-year 2025 total, per the company.
•
At the China International Import Expo, JD Health signed agreements with Pfizer, Merck, Takeda and over 20 other global pharma brands, extending cooperation from product launches to patient management and full-disease-cycle care.
•
On fulfilment, the "instant medicine delivery" overnight service now covers more than 300 cities nationwide; cold-chain delivery has been upgraded in multiple cities for temperature-controlled shipping of over 100 drug types. Offline, two JD Health general clinics opened in Beijing.
06

What will the market be watching next?

•
Can new-business loss narrowing continue? The pullback in losses at takeaway and Jingxi was the key driver of this quarter's profit acceleration; if the narrowing slows, profit growth will decelerate.
•
CECONOMY synergy timeline — completing the deal is step one; when revenue and cost synergies show up in the numbers will determine whether the overseas narrative holds.
•
JD Health AI monetisation pace — the surge in daily interactions proves demand exists, but the timetable for profit conversion remains uncertain. This reflects a company in transition: profit improvement has been delivered, but the next growth engines are still unproven.

市场有风险,内容仅供研究参考,不构成投资建议。

相关标的

1
  • KraneShares China Internet ETFKWEB.ETF-1.6%

    JD.com is one of KWEB's top holdings; its better-than-expected profit improvement bolsters overall earnings expectations for the China internet consumer sector.